Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

Almalki, Mussa H.; Alsuraikh, Moayad A.; Almalki, Eyad; Aziz, Faisal; Almazrouei, Raya; AlDahmani, Khaled M; Alshahrani, Fahad; Alaqeel, Meshal; Mahzari, Moeber; Ekhzaimy, Aishah

doi:10.1007/s11102-024-01383-2

Pituitary

2024

DOI: 10.1007/s11102-024-01383-2

|View full text |Cite|

Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

Mussa H. Almalki,

Moayad A. Alsuraikh,

Eyad Almalki

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite1

Independent3

Authors

Journals

Cited by 4 publications

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug induced hypoprolactinemia

Ioachimescu,

Kelestimur

2024

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Drug induced hypoprolactinemia

Ioachimescu,

Kelestimur

2024

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications

Haidenberg-David,

Sidauy-Adissi,

Moscona-Nissan

et al. 2024

Archives of Medical Research

View full text Add to dashboard Cite

Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice

Aldahmani,

AlMalki

2024

Journal of Diabetes and Endocrine Practice

Self Cite

View full text Add to dashboard Cite

Dopamine agonists (DAs) are the primary treatment for patients with hyperprolactinemia. However, there are potential risks of impulse control disorders (ICDs), particularly in those with predisposing factors. Early recognition of ICDs is essential, as reducing the dose or discontinuing the medication often resolves the issue. In some cases, alternative treatments like surgery may be necessary, especially for microprolactinoma or intrasellar macroprolactinoma. Future research should focus on identifying confounding risk factors for ICD development, confirming the presence of ICDs with the help of psychiatrists, documenting the severity of ICDs, and providing guidance on optimal management strategies upon detection of ICDs. We here briefly review the frequencies, risk factors and provide practical guidance on identification and management of ICDs in the context of managing pituitary disorders.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

Cited by 4 publications

References 26 publications

Drug induced hypoprolactinemia

Drug induced hypoprolactinemia

Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications

Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice

Contact Info

Product

Resources

About